Goodbye to hypos? 9 December 2014 Could hypoglycaemia soon be a thing of the past? A young scientist in the US has developed a non-insulin drug for people with type two diabetes that could help eliminate the risk of low-blood glucose hypos. Some people with type two diabetes use insulin to keep their blood glucose levels in check. If blood-glucose levels become too low, hypoglycaemia can occur and this can be life-threatening. To combat this, Arnab De, a scientist with a PhD in microbiology and immunology at Columbia University, developed a non-insulin drug in collaboration with fellow scientist Richard DiMarchi of Indiana University. “We find that there is a peptide hormone in the gut called GLP1 that increases the secretion of insulin only when the blood glucose is high,” Dr De said. “This effectively eliminates the risk of hypoglycemic shock. Another advantage is that GLP1 administration has been found to stimulate weight-loss. “The hormone offers the promise of revolutionising the treatment of type two diabetes and reduce obesity.” Read the article online at: http://www.diabetesqld.org.au/
Media releases 13 May 2026 Momentum builds following government response to diabetes inquiry The diabetes sector has welcomed the Federal Government’s response to the Parliamentary Inquiry into Diabetes, which provides in-principle support for... Continue Reading
Media releases 9 May 2026 Research reveals genes may determine who benefits most from popular weight-loss and diabetes medicines New research supported by Diabetes Australia has confirmed that a person’s genes can influence how well widely used diabetes medicines... Continue Reading
Blog 3 May 2026 Diabetes and Alzheimer’s: separating fact from fiction While research shows that type 2 diabetes is associated with a higher risk of Alzheimer's, many people with diabetes never develop dementia, and Alzheimer’s disease also affects people without diabetes. Continue Reading